Methods of treating b-cell proliferative disorder
AssigneeBeiGene Switzerland GmbH
InventorsJason PAIK, Tommi SALMI, Ying OU
Life of this patent
Estimating the term…
Abstract
Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one embodiment, zanubrutinib is administered at a dose of about 320 mg twice a day, or at a total daily dose of about 640 mg.
Claims30
A method of treating or delaying progression of a B-cell proliferative disorder in a patient, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, at a total daily dose of about 640 mg,
- wherein the patient is characterized by being administered with a moderate CYP3A inducer;
- and
- the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenstrom macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), or follicular lymphoma (FL).
A method of treating or delaying progression of a B-cell proliferative disorder in a patient, the method comprising
- selecting the patient who is being treated with a moderate CYP3A inducer;
- and
- administering to the selected patient zanubrutinib, or a pharmaceutically acceptable salt thereof, at a total daily dose of about 640 mg,
- wherein the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenstrom macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), or follicular lymphoma (FL).
A method of treating or delaying progression of a B-cell proliferative disorder in a patient receiving a moderate CYP3A inducer, the method comprising
- assessing the patient as to whether administration of the moderate CYP3A inducer can be avoided;
- selecting the patient who cannot avoid being treated with a moderate CYP3A inducer;
- and
- administering to the selected patient zanubrutinib, or a pharmaceutically acceptable salt thereof, at a total daily dose of about 640 mg,
- wherein the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenstrom macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), or follicular lymphoma (FL).
Dependencies are inferred from the claim text.